Toward more predictive genetic mouse models of Alzheimer's disease

Brain Research Bulletin

Volumn 122, Issue , 2016, Pages 1-11

  Onos, Kristen D ^a   Sukoff Rizzo, Stacey J ^a   Howell, Gareth R ^a,b   Sasner, Michael ^a  

^a JACKSON LABORATORY   (United States)

^b TUFTS UNIVERSITY   (United States)

Author keywords

Alzheimer's disease; Biomarkers; Genetic model; Genomics; Mouse model; Neuroinflammation; Preclinical model; Translational assays

Indexed keywords

BIOLOGICAL MARKER; TAU PROTEIN;

ALZHEIMER DISEASE; AMYLOIDOSIS; EXPERIMENTAL BEHAVIORAL TEST; EXPERIMENTAL MODEL; GENETIC ASSOCIATION; GENETIC ENGINEERING; GENETIC MODEL; GENETIC RISK; GENOME; IMMUNE RESPONSE; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; PREDICTIVE VALUE; PRIORITY JOURNAL; REPRODUCIBILITY; REVIEW; ANIMAL; DISEASE MODEL; GENETIC SCREENING; GENETICS; MOUSE; PROCEDURES;

ALZHEIMER DISEASE; ANIMALS; BIOMARKERS; DISEASE MODELS, ANIMAL; GENETIC TESTING; MICE;

EID: 84951762738     PISSN: 03619230     EISSN: 18732747     Source Type: Journal    
DOI: 10.1016/j.brainresbull.2015.12.003     Document Type: Review

References (82)

1. Bertram L., et al. Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database. Nat. Genet. 2007, 39(1):17-23.
2. Hall A.M., Roberson E.D. Mouse models of Alzheimer's disease. Brain Res. Bull 2012, 88(1):3-12.
3. Bubela T., Cook-Deegan R. Keeping score, strengthening policy and fighting bad actors over access to research tools. Nat. Biotechnol. 2015, 33(2):143-147.
4. Malthankar-Phatak G.H., et al. Amyloid deposition and advanced age fails to induce Alzheimer's type progression in a double knock-in mouse model. Aging Dis. 2012, 3(2):141-155.
5. Saito T., et al. Single App knock-in mouse models of Alzheimer's disease. Nat. Neurosci. 2014, 17(5):661-663.
6. Plucinska K., et al. Knock-in of human BACE1 cleaves murine APP and reiterates Alzheimer-like phenotypes. J. Neurosci. 2014, 34(32):10710-10728.
7. Melnikova T., et al. Reversible pathologic and cognitive phenotypes in an inducible model of Alzheimer-amyloidosis. J. Neurosci. 2013, 33(9):3765-3779.
8. Van der Jeugd A., et al. Cognitive defects are reversible in inducible mice expressing pro-aggregant full-length human Tau. Acta Neuropathol. 2012, 123(6):787-805.
9. Fowler S.W., et al. Genetic modulation of soluble Abeta rescues cognitive and synaptic impairment in a mouse model of Alzheimer's disease. J. Neurosci. 2014, 34(23):7871-7885.
10. Willem M., et al. eta-Secretase processing of APP inhibits neuronal activity in the hippocampus. Nature 2015, 526(7573):443-447.
11. Jackson H.M., et al. Clustering of transcriptional profiles identifies changes to insulin signaling as an early event in a mouse model of Alzheimer's disease. BMC Genomics 2013, 14:831.
12. Landel V., et al. Temporal gene profiling of the 5XFAD transgenic mouse model highlights the importance of microglial activation in Alzheimer's disease. Mol. Neurodegener. 2014, 9:33.
13. Morihara T., et al. Transcriptome analysis of distinct mouse strains reveals kinesin light chain-1 splicing as an amyloid-beta accumulation modifier. Proc. Natl. Acad. Sci. U. S. A. 2014, 111(7):2638-2643.
14. Burns T.C., et al. Mouse models rarely mimic the transcriptome of human neurodegenerative diseases: a systematic bioinformatics-based critique of preclinical models. Eur. J. Pharmacol. 2015, 759:101-117.
15. Vossel K.A., et al. Tau reduction prevents Abeta-induced axonal transport deficits by blocking activation of GSK3beta. J. Cell Biol. 2015, 209(3):419-433.
16. Shi L., et al. Cumulative effects of the ApoE genotype and gender on the synaptic proteome and oxidative stress in the mouse brain. Int. J. Neuropsychopharmacol. 2014, 17(11):1863-1879.
17. Teng E., et al. Low plasma ApoE levels are associated with smaller hippocampal size in the Alzheimer's disease neuroimaging initiative cohort. Dement. Geriatr. Cogn. Disord. 2015, 39(3-4):154-166.
18. Guerreiro R., et al. TREM2 variants in Alzheimer's disease. N. Engl. J. Med. 2013, 368(2):117-127.
19. Chan G., et al. CD33 modulates TREM2: convergence of Alzheimer loci. Nat. Neurosci. 2015, 18(11):1556-1558.
20. Benitez B.A., Cruchaga C., G.United States-Spain Parkinson's Disease Research TREM2 and neurodegenerative disease. N. Engl. J. Med. 2013, 369(16):1567-1568.
21. Rayaprolu S., et al. TREM2 in neurodegeneration: evidence for association of the p. R47H variant with frontotemporal dementia and Parkinson's disease. Mol. Neurodegener. 2013, 8:19.
22. Borroni B., et al. Heterozygous TREM2 mutations in frontotemporal dementia. Neurobiol. Aging 2014, 35(4):934. e7-10.
23. Cady J., et al. TREM2 variant p.R47H as a risk factor for sporadic amyotrophic lateral sclerosis. JAMA Neurol. 2014, 71(4):449-453.
24. Ulrich J.D., et al. Altered microglial response to Abeta plaques in APPPS1-21 mice heterozygous for TREM2. Mol. Neurodegener. 2014, 9:20.
25. Jay T.R., et al. TREM2 deficiency eliminates TREM2+ inflammatory macrophages and ameliorates pathology in Alzheimer's disease mouse models. J. Exp. Med. 2015, 212(3):287-295.
26. Wang Y., et al. TREM2 lipid sensing sustains the microglial response in an Alzheimer's disease model. Cell 2015, 160(6):1061-1071.
27. Vardarajan B.N., et al. Rare coding mutations identified by sequencing of Alzheimer disease genome-wide association studies loci. Ann. Neurol. 2015, 78(3):487-498.
28. Sander J.D., Joung J.K. CRISPR-Cas systems for editing, regulating and targeting genomes. Nat. Biotechnol. 2014, 32(4):347-355.
29. Ding Q., et al. Permanent alteration of PCSK9 with in vivo CRISPR-Cas9 genome editing. Circ. Res. 2014, 115(5):488-492.
30. Tucker B.A., et al. Duplication of TBK1 stimulates autophagy in iPSC-derived retinal cells from a patient with normal tension glaucoma. J. Stem Cell Res. Ther. 2014, 3(5):161.
31. Churchill G.A., et al. The diversity outbred mouse population. Mamm. Genome 2012, 23(9-10):713-718.
32. Yang H., et al. Subspecific origin and haplotype diversity in the laboratory mouse. Nat. Genet. 2011, 43(7):648-655.
33. Svenson K.L., et al. High-resolution genetic mapping using the mouse diversity outbred population. Genetics 2012, 190(2):437-447.
34. Rosen C., Zetterberg H. Cerebrospinal fluid biomarkers for pathological processes in Alzheimer's disease. Curr. Opin. Psychiatry 2013, 26(3):276-282.
35. Blennow K., et al. Amyloid biomarkers in Alzheimer's disease. Trends Pharmacol. Sci. 2015, 36(5):297-309.
36. Broersen K., Rousseau Schymkowitz F.J. The culprit behind amyloid beta peptide related neurotoxicity in Alzheimer's disease: oligomer size or conformation?. Alzheimers Res. Ther. 2010, 2(4):12.
37. Lasagna-Reeves C.A., et al. Preparation and characterization of neurotoxic tau oligomers. Biochemistry 2010, 49(47):10039-10041.
38. Handoko M., et al. Correlation of specific amyloid-beta oligomers with tau in cerebrospinal fluid from cognitively normal older adults. JAMA Neurol. 2013, 70(5):594-599.
39. Castillo-Carranza D.L., et al. Tau immunotherapy modulates both pathological tau and upstream amyloid pathology in an Alzheimer's disease mouse model. J. Neurosci. 2015, 35(12):4857-4868.
40. Zahs K.R., Ashe K.H. beta-Amyloid oligomers in aging and Alzheimer's disease. Front. Aging Neurosci. 2013, 5:28.
41. Koppel J., et al. CB2 receptor deficiency increases amyloid pathology and alters tau processing in a transgenic mouse model of Alzheimer's disease. Mol. Med. 2014, 20:29-36.
42. Calafate S., et al. Synaptic contacts enhance cell-to-cell tau pathology propagation. Cell Rep 2015, 11(8):1176-1183.
43. Iliff J.J., et al. A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid beta. Sci. Transl Med. 2012, 4(147):147ra111.
44. Jessen N.A., et al. The glymphatic system: a beginner's guide. Neurochem. Res. 2015, 40(12):2583-2599.
45. Xie L., et al. Sleep drives metabolite clearance from the adult brain. Science 2013, 342(6156):373-377.
46. Huang Y., et al. Effects of age and amyloid deposition on Abeta dynamics in the human central nervous system. Arch. Neurol. 2012, 69(1):51-58.
47. Crowley K. Sleep and sleep disorders in older adults. Neuropsychol. Rev. 2011, 21(1):41-53.
48. Pace-Schott E.F., Spencer R.M. Age-related changes in the cognitive function of sleep. Prog. Brain Res. 2011, 191:75-89.
49. Mander B.A., et al. beta-Amyloid disrupts human NREM slow waves and related hippocampus-dependent memory consolidation. Nat. Neurosci. 2015, 18(7):1051-1057.
50. Wisor J.P., Schmidt Clegern M.A.W.C. Evidence for neuroinflammatory and microglial changes in the cerebral response to sleep loss. Sleep 2011, 34(3):261-272.
51. Mosher K.I., Wyss-Coray T. Microglial dysfunction in brain aging and Alzheimer's disease. Biochem. Pharmacol. 2014, 88(4):594-604.
52. Savonenko A.V., et al. Cannabinoid CB2 receptors in a mouse model of abeta amyloidosis: immunohistochemical analysis and suitability as a PET biomarker of neuroinflammation. PLoS One 2015, 10(6):e0129618.
53. Solas M., et al. CB2 receptor and amyloid pathology in frontal cortex of Alzheimer's disease patients. Neurobiol. Aging 2013, 34(3):805-808.
54. Grunblatt E., et al. Gene expression as peripheral biomarkers for sporadic Alzheimer's disease. J. Alzheimers Dis. 2009, 16(3):627-634.
55. Nunez E., et al. Glial expression of cannabinoid CB(2) receptors and fatty acid amide hydrolase are beta amyloid-linked events in Down's syndrome. Neuroscience 2008, 151(1):104-110.
56. Poirier R., et al. Enhanced dentate gyrus synaptic plasticity but reduced neurogenesis in a mouse model of amyloidosis. Neurobiol. Dis 2010, 40(2):386-393.
57. Ziabreva I., et al. Altered neurogenesis in Alzheimer's disease. J. Psychosom. Res. 2006, 61(3):311-316.
58. Winner B., Kohl Z., Gage F.H. Neurodegenerative disease and adult neurogenesis. Eur. J. Neurosci. 2011, 33(6):1139-1151.
59. Crews L., Rockenstein Masliah E.E. APP transgenic modeling of Alzheimer's disease: mechanisms of neurodegeneration and aberrant neurogenesis. Brain Struct. Funct. 2010, 214(2-3):111-126.
60. Singer B.H., et al. Compensatory network changes in the dentate gyrus restore long-term potentiation following ablation of neurogenesis in young-adult mice. Proc. Natl. Acad. Sci. U. S. A. 2011, 108(13):5437-5442.
61. Fuster-Matanzo A., et al. Role of neuroinflammation in adult neurogenesis and Alzheimer disease: therapeutic approaches. Mediators Inflamm. 2013, 2013:260925.
62. Moriyama M., et al. Complement receptor 2 is expressed in neural progenitor cells and regulates adult hippocampal neurogenesis. J. Neurosci. 2011, 31(11):3981-3989.
63. Di Marzo V., Stella N., Zimmer A. Endocannabinoid signalling and the deteriorating brain. Nat. Rev. Neurosci. 2015, 16(1):30-42.
64. Methia N., et al. ApoE deficiency compromises the blood brain barrier especially after injury. Mol. Med. 2001, 7(12):810-815.
65. Bell R.D., et al. Apolipoprotein E controls cerebrovascular integrity via cyclophilin A. Nature 2012, 485(7399):512-516.
66. Soto I., et al. APOE stabilization by exercise prevents aging neurovascular dysfunction and complement induction. PLoS Biol. 2015, 13(10).
67. Wu Z., et al. Role of the MEOX2 homeobox gene in neurovascular dysfunction in Alzheimer disease. Nat. Med. 2005, 11(9):959-965.
68. Obermeier B., Daneman R., Ransohoff R.M. Development, maintenance and disruption of the blood-brain barrier. Nat. Med. 2013, 19(12):1584-1596.
69. Rodgers S.P., et al. Transgenic APP expression during postnatal development causes persistent locomotor hyperactivity in the adult. Mol. Neurodegener. 2012, 7:28.
70. Webster S.J., et al. Using mice to model Alzheimer's dementia: an overview of the clinical disease and the preclinical behavioral changes in 10 mouse models. Front. Genet. 2014, 5:88.
71. Bussey T.J., et al. New translational assays for preclinical modelling of cognition in schizophrenia: the touchscreen testing method for mice and rats. Neuropharmacology 2012, 62(3):1191-1203.
72. Romberg C., Bussey T.J., Saksida L.M. Paying more attention to attention: towards more comprehensive cognitive translation using mouse models of Alzheimer's disease. Brain Res. Bull. 2013, 92:49-55.
73. Romberg C., et al. Impaired attention in the 3xTgAD mouse model of Alzheimer's disease: rescue by donepezil (Aricept). J. Neurosci. 2011, 31(9):3500-3507.
74. van der Staay F.J., Steckler T. The fallacy of behavioral phenotyping without standardisation. Genes Brain Behav. 2002, 1(1):9-13.
75. Steckler T. Preclinical data reproducibility for R&D-the challenge for neuroscience. Psychopharmacology (Berl.) 2015, 232(2):317-320.
76. Kilkenny C., et al. Survey of the quality of experimental design, statistical analysis and reporting of research using animals. PLoS One 2009, 4(11):e7824.
77. Kilkenny C., et al. Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. J. Pharmacol. Pharmacother. 2010, 1(2):94-99.
78. Landis S.C., et al. A call for transparent reporting to optimize the predictive value of preclinical research. Nature 2012, 490(7419):187-191.
79. Steward O., Balice-Gordon R. Rigor or mortis: best practices for preclinical research in neuroscience. Neuron 2014, 84(3):572-581.
80. Unger E.F. All is not well in the world of translational research. J. Am. Coll. Cardiol. 2007, 50(8):738-740..
81. Sukoff Rizzo, S.J., 2015. Mouse Models for Drug Discovery, ed. P.a. Wiles.
82. Rizzo S.J., et al. Future viable models of psychiatry drug discovery in pharma. J. Biomol. Screen 2013, 18(5):509-521.